Navigation Links
Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model
Date:4/8/2008

Research To Be Presented at American Association of Immunologists Meeting

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for type 1 diabetes mellitus, according to research being presented at the American Association of Immunologists meeting in San Diego, California on April 8, 2008. Using Rigel's R788, researchers from the Department of Medicine at Columbia University Medical Center have shown that blocking Syk kinase in a well-established murine model of type 1 diabetes, delayed the onset of diabetes and prolonged survival. A reduction in the production of insulin-specific autoantibodies, an early event in type 1 diabetes pathogenesis, was also observed.

"Inhibition of the Syk kinase has the potential to reduce both autoantibody production and disarm its pathogenic consequences," said Raphael Clynes M.D., Ph.D., assistant professor in Medicine and Microbiology at Columbia University's College of Physician's and Surgeons. "In diabetes, autoantibodies against islet cells appear before the actual onset of disease providing the opportunity to intervene and disable these early events prior to immune destruction of the insulin-producing cells in the pancreas. The protection we see in these mouse models suggests that pharmacologic blockade of Syk with R788 may provide a good therapeutic strategy to treat and potentially prevent the onset or advancement of type 1 diabetes," he added.

Type 1 Diabetes and R788

According to the Juvenile Diabetes Research Foundation, type 1 diabetes, also called juvenile diabetes or insulin-dependent diabetes, occurs when the body's immune system attacks and destroys beta cells within the islets of the pancreas. Beta cells normally produce insulin, a hormone that helps the body move glucose from food into the body's cells to be used for energy. If insulin cannot be produced, the glucose remains in the blood and ultimately may damage organs and tissues. Therefore, insulin replacement via injection once or more each day is vital to patients with type 1 diabetes.

Extensive studies of Rigel's oral Syk inhibitor, R788, have demonstrated results indicating its potential value in modulation of the immune response in a variety of autoimmune disorders. As such, R788 is presently in clinical trials for rheumatoid arthritis, immune thrombocytopenic purpura, and B-cell lymphoma.

This work was supported by funds provided by the Juvenile Diabetes Research Foundation and the Naomi Berrie Diabetes Center at Columbia University Medical Center in Manhattan.

Note: R788 is a prodrug of R406, which is cited in the research study.

About Rigel (http://www.Rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the preclinical data and plans, the potential efficacy and commercial potential of R788 and Rigel's plans to pursue further preclinical development thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "may," "expect," "potential," "indicate," suggest," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, potential problems that may arise in the clinical testing and approval process and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-K for the year ended December 31, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: rrodriguez@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.430.3777

Email: susan@alchemyemail.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
2. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
3. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
6. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
7. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
8. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
9. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
10. Newly Approved HIV Drug Shows Great Promise
11. Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... BARBARA, Calif. and INDIANAPOLIS ... (NYSE: LLY ) and the William Sansum ... the lives of Latino people affected by diabetes through ... tremendous burden of diabetes and cardiovascular disease bears a ... United States ," said David Kerr , ...
(Date:3/23/2017)... , March 23, 2017  The U.S. Food ... (avelumab) for the treatment of adults and pediatric patients ... (MCC), including those who have not received prior chemotherapy. ... a rare, aggressive form of skin cancer. ... cancers, patients with a rare form called Merkel cell ...
(Date:3/23/2017)... MOINES, Iowa , March 23, 2017   ... and career resource, has partnered with Indiana Biosciences ... Indiana organizations and educational institutions to bring ... with the first-ever BioIndiana Hotbed map, an artistic representation ... framed print was presented to Vice President Mike ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter ... the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to ... premier prehospital trauma education developed in cooperation with the American College of Surgeons ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation lab specializing ... of a Greenville, South Carolina location. The lab has set up shop ... “We’ve been working with South Carolina clients for years from our office here in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Huebner Road. The clinic is the group’s 7th location in San Antonio and 23rd ... PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her ... 9--24, 2017. This sacred and spiritual journey during the Summer Solstice will ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, Dr. ... for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, ... obstructive type, is increasingly being treated at dental offices with newly developed procedures ...
Breaking Medicine News(10 mins):